drugset
drugset / Trial / NCT04687020

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

NCT04687020 ↗

Phase 4 Active not recruiting 9 enrolled NS Pharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.

Timeline

Start
2021-06-10
Primary completion
2032-09
Completion
2032-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Viltolarsen Unknown 80 mg/kg Intravenous

Indications

Duchenne muscular dystrophy